It was investigator lead from before the company pivot and using RC110. If there were to be a P3 trial for it, it would need to be with the same formulation. I would assume these announcement are more a formality on races part due to compliance.
The upcoming AML trial will be using rc220, which will be relevant to race's pipeline, even if there may be no current funding strategies for further trials for AML.
Ann: Bisantrene Phase 2 AML Trial Successful Concludes, page-37
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.015(1.02%) |
Mkt cap ! $252.2M | |||
| Open | High | Low | Value | Volume |
| $1.49 | $1.49 | $1.45 | $112.1K | 76.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 3371 | 2 |
View Market Depth
| Last trade - 11.23am 14/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |